自体外周血造血干细胞移植治疗非霍奇金淋巴瘤56例临床分析  

Autologous peripheral blood hematopoietic stem cell transplantation in 56 patients with non-hodgkin's lymphoma

作　　者：张端众[1] 肖青[1] 张红宾[1] 唐晓琼[1] 王建渝[1] 王欣[1] 杨泽松[1] 陈建斌[1] 刘林[1] 王利[1] 

机构地区：[1]重庆医科大学附属第一医院血液科,重庆400016

出　　处：《重庆医科大学学报》2015年第1期154-158,共5页Journal of Chongqing Medical University

基　　金：国家自然科学基金资助项目(编号:81250034);重庆市卫生局资助项目(编号:2013-2-023);重庆市教委资助项目(编号:2013)

摘　　要：目的：探讨自体外周血造血干细胞移植（autologous peripheral blood stem cell transplantation,APBSCT）治疗非霍奇金淋巴瘤（non-Hodgkin’s lymphoma,NHL）的临床疗效。方法：回顾性分析2009年2月至2013年10月在我院行APBSCT的NHL患者56例,其中男37例,女19例,中位年龄44岁（16~69）岁,缓解病例46例,部分缓解7例,复发难治3例。结果：56例移植患者中55例获造血重建,1例未造血重建。中性粒细胞绝对值〉0.5×109个/L的中位时间9.5 d（7~18 d）、血小板计数〉20×109个/L的中位时间11.5 d（6~24 d）。24例患者于粒细胞缺乏期时出现发热,5例出现轻中度腹泻,1例出现轻度肝功能损害,1例出现带状疱疹。所有患者随访截止于2014年4月1日,中位随访时间20.25月（3.0~60.5月）。45例存活（其中5例带病生存）,10例复发,11例死亡（其中5例死于复发）。复发率为17.9%,总生存率（overall survival,OS）、无病生存率（disease free survival,DFS）分别为80.4%、71.4%。结论：APBSCT是治疗NHL的有效手段,造血重建快,并发症少。Objective：To study the clinical efficacy of autologous peripheral blood hematopoietic stem cell transplantation（APBSCT）in the treatment of non-Hodgkin’s lymphoma（NHL）. Methods：A total of 56 patients who underwent APBSCT from February 2009 toOctober 2013 in the hospital were enrolled in the study. There were 37 males and 19 females with a median age of 44 years（16-69 years）;46 cases were in remission,7 cases in partial remission and 3 cases in relapsed or refractory. Results：Among56 patients treated by APBSCT,55 patients obtained hematopoietic reconstitution. The median time for neutrophils recovery（〉0.5×109/L）was 9.5（7-18）d and platelet recovery（〉20×109/L） was 11.5（6-24） d. Twenty-four patients experienced fever during granulocyte lack phase,5 patients experiencedmild-to-moderate diarrhea,one patient had mild liver function damage and one patient had herpes zoster. All patients were followed up till the 1st April,2014,and the median follow-up time was 20.25（3-60.5）months. Forty-five cases survived（5 cases alive with disease）;10 cases relapsed;11 cases died（5 cases died of recurrence）. The recurrence rate was 17.9%. Overall survival and diseasefree survival were 80.4% and 71.4% respectively. Conclusion：With the advantages of quicker hematopoietic reconstruction and fewer non-Hodgkin’s lymphoma,APBSCT is effective in the treatment of NHL.

关 键 词：造血干细胞移植 自体 非霍奇金淋巴瘤 

分 类 号：R55[医药卫生—血液循环系统疾病]